Pacgen Life Science Corporation, formerly Pacgen Biopharmaceuticals Corporation, is a life science technology transfer company focused on the commercial development of therapeutic drug candidates up to Phase II. The Company identifies therapeutic drug candidates globally, and develops these drug candidates, with collaborative partners. As of March 31, 2012, the Company has two product pipelines in its technology portfolio: PAC-113, an anti-fungal for the treatment of oral Candidiasis, and PAC-G31P, a peptide therapeutic designed to treat inflammatory diseases characterized by non-beneficial neutrophil. The Company is developing PAC-G31P to treat inflammatory diseases. The Company is developing PAC- 113 in a mouthrinse formulation for the topical treatment of oral Candidiasis.